Merck: priority review in metastatic breast cancer.
(CercleFinance.com) - AstraZeneca and Merck said on Wednesday that the US Food and Drug Administration (FDA) has granted priority review for a supplemental new drug application (sNDA) for the use of Lynparza tablets in patients with metastatic breast cancer.
This is the third US indication submission for Lynparza, which has been used to treat over 3,000 advanced ovarian cancer patients since December 2014.
A decision will be made in the first quarter of 2018.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This is the third US indication submission for Lynparza, which has been used to treat over 3,000 advanced ovarian cancer patients since December 2014.
A decision will be made in the first quarter of 2018.
Copyright (c) 2017 CercleFinance.com. All rights reserved.